June 2026 Research Update

One June study made the autoimmune form of pulmonary alveolar proteinosis (aPAP) feel less mysterious by showing that not all anti-GM-CSF antibodies behave the same. The study linked more severe disease to antibodies that bind GM-CSF very tightly and target certain parts of the molecule, rather than to the total amount of antibody in the blood. In plain terms, the "shape" and "stickiness" of the antibodies appeared to matter for how strongly they block GM-CSF and how severe aPAP looks. [1]

In this research, antibodies were grouped by where they attach on GM-CSF, and the group called class 1 (targeting A/BD/D regions) showed a strong link between tight binding and strong GM-CSF blocking. These high-affinity class 1 antibodies were more common in people with more severe aPAP, while a different antibody group (class 2, targeting B/C regions) did not show the same clear relationship. This helps clarify why two people can both test positive for anti-GM-CSF antibodies but have very different disease severity. [1]

The same study also tested whether these antibodies can directly cause a PAP-like problem in a specialized mouse model with human immune components. High-affinity class 1 antibodies could induce PAP in that model, which supports the idea that some antibody types are more likely to be disease-driving than others. This is still not the same as proving how any one patient will do, but it strengthens the biological explanation for aPAP. [1]

For patients and caregivers, this mainly adds understanding rather than changing anything immediately. It suggests that future tests might need to look beyond a simple positive/negative antibody result or a total antibody level, because severity may depend on which antibodies a person has and how strongly they block GM-CSF. What remains uncertain is how soon (or whether) these detailed antibody measurements will become part of routine care, and how they relate to response to treatments like inhaled GM-CSF in different people. [1]

This month added a broader real-world view of pulmonary alveolar proteinosis by placing it inside a national registry of rare interstitial lung diseases. In this cohort, PAP represented about a quarter of enrolled patients, and the registry tracked outcomes for years rather than weeks. The picture that emerged is that PAP sat in the middle of the severity range compared with several other rare lung conditions studied in the same system. [2]

Over a median follow-up of about 69.5 months, the registry reported a mortality of 6.2% for PAP, while other diseases in the registry had higher or lower rates. The study also described treatment patterns, including that whole-lung lavage was recorded in 23.5% of PAP patients in this cohort. This kind of information helps patients understand how PAP care often looks in routine practice, even though a registry cannot show which treatment caused which outcome. [2]

For patients, this evidence may matter now as context: it describes what PAP looked like across many people in one country and what kinds of treatments were commonly used. It does not compare treatments head-to-head, so it cannot tell an individual person which approach will work best. It can still help clarify expectations about the kinds of complications and follow-up that are tracked over time in real-world settings. [2]

The case reports this month showed that PAP often appears alongside other medical issues that can shape how it is recognized and managed. Across different situations, clinicians used a combination of confirming the type of PAP (autoimmune vs secondary) and then choosing supportive or PAP-directed approaches such as whole-lung lavage and inhaled GM-CSF. Taken together, these reports reinforce that the same-looking lung findings on scans can come from different underlying causes, which can matter for what is tried next. [3] [4] [5] [6] [7] [8] [9] [10]

Several autoimmune PAP reports described improvement after inhaled GM-CSF (sargramostim), sometimes combined with whole-lung lavage. One adult with worsening after segmental bronchoscopic lavage declined whole-lung lavage and improved substantially after 6 months of inhaled sargramostim, including a drop in the oxygen gradient from 21.8 to 1.1 mmHg. Another report described recurrent autoimmune PAP years after lung transplantation with marked radiographic clearing and symptom relief after inhaled sargramostim plus two sequential whole-lung lavages. [3] [8]

Autoimmune PAP also appeared in the setting of unusual or prolonged infections, where anti-GM-CSF antibodies were part of the explanation. One patient with chronic disseminated blastomycosis was diagnosed with autoimmune PAP and improved in symptoms and imaging after whole-lung lavage and inhaled GM-CSF, but still needed oxygen during sleep and activity. Another patient had high anti-GM-CSF antibodies and experienced multiple serious infections before later developing radiologic changes consistent with PAP; PAP-directed therapy was deferred because respiratory symptoms were minimal, and the person remained clinically stable with surveillance. [4] [7]

These reports also highlighted secondary PAP, where something else disrupts the lung's clean-up cells. One worker with indium-tin-oxide exposure had secondary PAP confirmed by indium found in blood, lavage fluid, and lung tissue; whole-lung lavage briefly improved oxygen levels, but imaging progressed to pulmonary fibrosis within months despite additional medications. Another post-transplant patient developed secondary PAP possibly related to ruxolitinib for graft-versus-host disease and improved clinically and on CT after stopping ruxolitinib, before later relapse and treatment for Mycobacterium intracellulare. [6] [9]

Pediatric reports added longer-term perspective and genetic context. A 12-year-old with autoimmune PAP required oxygen and multiple whole-lung lavages over 2 years, then gradually improved and was described as in remission with stable breathing tests several years later. A small series described 4 children with PAP and progressive childhood interstitial lung disease linked to biallelic IARS gene changes, with laboratory findings pointing to macrophage dysfunction and surfactant build-up. [5] [11]

Finally, one report focused on autoimmune PAP triggered by cancer drugs called tyrosine kinase inhibitors (TKIs), summarizing 5 reported cases including brigatinib. Time from starting a TKI to PAP was reported with a median of 5 months, and patients were treated with approaches such as whole-lung lavage or inhaled GM-CSF, with mixed outcomes including deaths related to respiratory failure or underlying disease progression. This adds to awareness that medication-triggered autoimmune PAP can occur, but the small number of cases limits what can be predicted for any individual patient. [10]

For patients, these reports may matter now mainly by expanding the list of real-life situations where PAP has been identified and by showing how diagnosis is often confirmed (for example, anti-GM-CSF antibodies for autoimmune PAP, or exposure and other triggers for secondary PAP). They provide examples where inhaled GM-CSF and whole-lung lavage were followed by improvement in some individuals, including after transplant and in pediatric autoimmune PAP, but single-patient experiences cannot guarantee similar results for others. What remains uncertain is which patients benefit most from each approach and how triggers like infections, medications, or workplace exposures change the expected course. [3] [4] [5] [6] [7] [8] [9] [10] [11]

This month included animal studies that tried to explain why indium exposure can lead to a secondary PAP-like condition, and what might reduce it in that setting. In rats, indium nanoparticle exposure produced a chain of lung changes that included PAP-like surfactant build-up and signs of developing scarring. Another rat experiment tested medicines aimed at macrophage lipid handling and reported that some reduced the PAP-like build-up in the model. [12] [13]

In one study, dispersed indium-tin oxide nanoparticles led to progressive lung injury up to 12 weeks, including PAP-like changes, lipid build-up in macrophages, and interstitial fibrosis. The authors linked these findings to cell stress signals such as reactive oxygen species and mitochondrial damage in the model. This helps explain a possible biological path from exposure to surfactant build-up and later scarring, but it remains laboratory evidence rather than a proven timeline for people. [12]

In a second rat study using indium oxide nanoparticles, pioglitazone and indomethacin were reported to markedly reduce foamy macrophage accumulation and surfactant overload, compared with aspirin and naproxen which had limited effects. The study also noted a stronger effect when these drugs were given before the PAP-like pathology was established, while established disease was only partly reversed. These results point to macrophage lipid regulation as a research direction, but they do not show that these medications will help people with secondary PAP. [13]

For patients, this is early research that mainly matters for future understanding of secondary PAP related to workplace or environmental exposures. It gives a clearer biological explanation for why indium can cause PAP-like lung changes and scarring in an animal model, and it identifies drug targets that reduced disease features in rats. What remains uncertain is whether these pathways work the same way in humans, and whether any of the tested drugs would be safe or effective for people with secondary PAP. [12] [13]

Two June studies broadened the picture of pediatric PAP by focusing on inherited causes and what life can look like beyond breathing symptoms. One study expanded the set of genes tied to childhood interstitial lung disease with PAP, pointing to immune-cell problems that may impair surfactant clearance. Another followed children with MARS1-related PAP and found relatively consistent neurodevelopmental and adaptive skill difficulties across the group. [11] [14]

In 4 children with PAP and progressive childhood interstitial lung disease, biallelic IARS gene changes were identified, and lab work suggested macrophage and monocyte dysfunction with lipid and surfactant build-up. The study reported findings like lipoprotein accumulation in lavage fluid and changes inside alveolar macrophages that fit with impaired clean-up of surfactant. This strengthens the idea that in some children, PAP is part of a broader inherited condition affecting immune cells, not only the lungs. [11]

In a separate cohort of 16 children with MARS1-related PAP who were treated with methionine, standardized testing found average cognitive scores in the borderline to mild intellectual disability range and adaptive behavior deficits across several areas. The authors described the impairments as relatively homogeneous across the cohort, meaning many children showed similar kinds of challenges. This adds concrete information about day-to-day functioning that families may face in this specific genetic form of PAP. [14]

For families affected by childhood-onset PAP, these findings may matter now by clarifying that some forms are part of inherited conditions that can affect development as well as the lungs. The neurodevelopment study does not show that methionine fails or succeeds for lung disease, but it does show that developmental challenges were still common in this group despite early treatment. What remains uncertain is how widely these results apply across different genetic causes of pediatric PAP, and which supports best address the non-lung impacts over time. [11] [14]

One study looked at how often autoimmune PAP (APAP) overlaps with other autoimmune diseases, and what that overlap looks like. It found that a minority of APAP patients had another autoimmune condition, and those patients tended to be older and more often female than APAP patients without autoimmune comorbidity. This adds a clearer picture that APAP can occur in people already living with autoimmune illness and related medications. [15]

Among 100 APAP patients at one center, 10 had another autoimmune disease, most commonly conditions like rheumatoid arthritis, and in 9 of the 10 the autoimmune disease came first. Eight of these 10 patients were receiving immunosuppressive therapy when APAP was diagnosed, and the report described CT improvement after stopping prednisolone in 2 patients. During follow-up, 1 patient died and pulmonary fibrosis developed in 3 patients in this subgroup. [15]

For patients who have APAP plus another autoimmune disease, this study may matter now as context for how commonly these conditions overlap and what was observed in one center. It raises a research concern that some immunosuppressive medicines might worsen APAP in some people, but the study design cannot prove cause and effect. What remains uncertain is which specific drugs or patient situations carry the most risk, and how best to balance treatment of the autoimmune disease with the lung condition in future studies. [15]